organ inorgan growth led revenu ebitda beat quarter fx
favor impact revenu impact profit metric compani rais
revenu guidanc accordingli maintain valuat bring
pt updat estim base ev/ ebitda
net debt s/o reiter neutral rate
growth total revenu growth constant currenc contract backlog
billion includ award sinc merger quarter
larg project biopharma compani leverag iqv abil identifi high-
perform site larg pipelin virtual trial solut synthet
clinic trial compar singl arm popul retrospect real world data
support label expans intrigu natur work believ
technolog reduc cost time involv bring drug market
howev never-end debat data better data remain
seen de-identifi rwe data set repurpos use clinic studi
given inher bia inconsist data set captur
invest cota help drive inorgan revenu cota
data analyt compani leverag real world evid data support clinic research
well clinic practic result minor stake partner
memori sloan ketter institut explor cancer care believ
expand data pool could acceler analyt capabl
merger synergi remain track approach two-year anniversari
announc merger combin compani track deliv
cost synergi year-end cost save initi gener ebitda
margin improv quarter off-set invest intend drive
organ growth especi area data scienc replatform global
chang pharma industri impact spend drug research revers
current increas outsourc trend pharma industri averag leverag
balanc sheet impact opportun
iqvia largest cro industri expertis across major therapeut
oper countri
ebitda net
debt s/o
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
number revenu beat pjc consensu ebitda beat
pjc estim consensu ep beat pjc consensu
expect revenu vs pjc/consensu ebitda
vs pjc ep vs consensu
fx pass-through expens alloc contribut revenu beat
profit rais revenu guidanc vs pjc
consensu re-affirmed ebitda ep year
sale
compani document piper jaffray co
compani document piper jaffray co
page
revenu
revenu reimburs expens
consolid incom oper
loss extinguish debt
sale busi
incom tax
tax incom
equiti earn unconsolid affili
loss incom non-control interest
revenu
current disclosur inform compani locat
